IFN-β1b (recombinant human)

Home
Ligands
IFN-β1b (recombinant human)

GtoPdb Ligand ID: 8340

Synonyms: Betaferon® | Betaseron® | Extavia® | IFNb1b

IFN-β1b (recombinant human) is an approved drug (FDA (1993), EMA (1995))

Compound class: Peptide or derivative

Comment: Compared to the sequence of endogenous IFN-β, IFN-β1b has a Ser to Cys substitution at position 17, but does not retain the glycosylation site at Asn80. It also lacks the initiating Met. This recombinant peptide is produced in E.coli.

Summary
Biological activity
Clinical data
References
Structure
Similar ligands
Immunopharmacology

No information available.

No information available.

Summary of Clinical Use
Like IFN-β1a (recombinant human), IFN-β1b is used to treat relapsing forms of multiple sclerosis [1-2].

Summary of Clinical Use

Like IFN-β1a (recombinant human), IFN-β1b is used to treat relapsing forms of multiple sclerosis [1-2].

Mechanism Of Action and Pharmacodynamic Effects
IFN-β1b activates Type I interferon receptors and induces expression of genes involved in antiviral, immunomodulatory and antiproliferative effects. The mechanism of action underlying the therapeutic benefit of IFN-β1b therapy remains unclear.

Mechanism Of Action and Pharmacodynamic Effects

IFN-β1b activates Type I interferon receptors and induces expression of genes involved in antiviral, immunomodulatory and antiproliferative effects. The mechanism of action underlying the therapeutic benefit of IFN-β1b therapy remains unclear.